当前位置:首页>产品中心>单抗/多抗>Ocaratuzumab ELISA Kit|Ocaratuzumab ELISA试剂盒(靶标:)

Ocaratuzumab ELISA Kit|Ocaratuzumab ELISA试剂盒(靶标:)

  • 货号:RB9TDY257078
  • 价格:面议
  • 点击:406

产品介绍

产品参数

应用ELISA
检测方法Colorimetric
灵敏度0.156 μg/ml
检测范围0.31-5 μg/mL
回收率80-120%
样本类型Plasma, Serum
检测类型Quantitative
稳定性和储存The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
运输条件2-8 ℃
登录号P11836
背景信息Ocaratuzumab, previously known as AME-133v, is a humanized IgG1 type monoclonal antibody targeted at CD20 antigen, which is expressed on B-lymphocytes. Ocaratuzumab is a novel Fc-engineered monoclonal antibody designed by Applied Molecular Evolution in an attempt to induce effective antibody-dependent cell-mediated cytotoxicity (ADCC) at very low concentrations that may facilitate sub-cutaneous dosing. Libraries of antibody Fab fragment regions were generated with codon substituted variations of the antibody complementarity determining regions (CDRs) inserted into human antibody light and heavy chain germline frameworks. Then, the researchers expressed and selected mutants based on increased affinity for CD20. A variable region with increased binding activity for CD20 was selected and developed as ocaratuzumab. This drug is currently being developed by Mentrik Biotech and has been investigated in the trial for the treatment of cancer and autoimmune disorders. The pre-clinical trials of ocaratuzumab in follicular lymphoma was conducted in the United States (US) and Japan in phase I/II, and a Phase I trial was conducted in US rheumatoid arthritis patients. In addition, a phase III trial in relapsed follicular lymphoma patients is underway. Compared to rituximab, ocaratuzumab was shown to ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC in pre-clinical studies. The use of ocaratuzumab in other oncology and rheumatology indications has also been developed.
别名AME-133v, LY2469298, 1169956-08-4
备注For Research Use Only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 612
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 805
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 841
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 726
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 656
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 662
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 381
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 651
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 731
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 704
Anti-Human CD42b/GP1BA Recombinant Antibody|抗人CD42b/GP1BA重组抗体(靶标:人血小板糖蛋白Ibα链/CD42b) 834
Anti-Human JMJD1C Polyclonal Antibody|抗人JMJD1C多克隆抗体(靶标:人Jumonji结构域含蛋白1C) 670
Anti-Human ITGB6 Polyclonal Antibody|抗人ITGB6多克隆抗体(靶标:人整合素β6亚基) 861
Anti-Mouse IL33 Recombinant Antibody |抗小鼠IL33重组抗体(靶标:小鼠白细胞介素33) 597
Anti-Mouse CD1d/CD1.1 Recombinant Antibody|抗小鼠CD1d/CD1.1重组抗体(靶标:小鼠CD1d分子) 791
Anti-Mouse α5β1 (ITGA5 & ITGB1) Recombinant Antibody|抗小鼠α5β1(ITGA5和ITGB1)重组抗体(靶标:小鼠整合素α5β1复合物) 784
Anti-Mouse VEGFA Recombinant Antibody|抗小鼠VEGFA重组抗体(靶标:小鼠血管内皮生长因子A) 488
总计 33037 个记录,共 1652 页,当前第 1652 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00